Investor Presentaiton
Strategic Area MAP
Medical
Business
■ Accelerated existing business growth →Toward strengthening new business.
development and business growth through M&As
Business fields
Position
[ Life Science Domain in 2030]
Diagnostics
Pharmaceutical Sciences
✓ Clinical chemistry/Immunology
CRO
✓ Blood coagulation (area expansion)
Diabetes
✓ Safety evaluation
CDMO
Small molecule API
✓ Medium molecule bio analysis
✓ Enzyme
✓ New modalities
✓ POC
✓ Blood collection tubes
✓ New fields such as genetics
(U.S. base)
Core
SEKISUI
Cell culture solutions
(Cultivation materials and equipment)
Digital health (programmed medical devices)
Innovation areas
<Molecular Diagnostics (MDx)
Development Center>
Work to enter the regenerative and genetic CDMO field with a focus on animal-free
materials for medical use based on the Group's core PVB resin technology
Regenerative medicine and Gene therapy
Cultivation materials and equipment
processes
SEKISUI
DIAGNOSTICS
Regenerative
(1)Chemosynthetic
(2)Synthetic culture
medicine
Allogeneic transplantation
transplantation
scaffolding materials
supplements
Autologous
Collection
6740
Conveyance (4)
(4) Conveyance
(3)Cell-culture
Medium
Gene
therapy
(1)(2)(3)
SEKISUI DIAGNOSTICS, LLC, San Diego
Extraction
Culturing
Gen
introduction
Copyright© SEKISUI CHEMICAL CO., LTD.
SEKISUI
(5)Gene
(4) Cell-transport introduction
containers
43View entire presentation